Inventiva SA (IVA)
| Market Cap | 361.73M |
| Revenue (ttm) | 8.50M |
| Net Income (ttm) | -49.64M |
| Shares Out | 40.87M |
| EPS (ttm) | -1.32 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 8,836 |
| Open | 9.00 |
| Previous Close | 8.80 |
| Day's Range | 8.85 - 9.10 |
| 52-Week Range | 8.00 - 16.93 |
| Beta | 0.95 |
| Analysts | Buy |
| Price Target | 31.69 (+258.1%) |
| Earnings Date | Mar 3, 2022 |
About IVA
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. Th...
Financial Performance
In 2021, Inventiva's revenue was $8.50 million, an increase of 61.52% compared to the previous year's $5.26 million. Losses were -$49.64 million, 47.6% more than in 2020.
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for IVA stock is "Buy." The 12-month stock price forecast is 31.69, which is an increase of 258.08% from the latest price.
News
Inventiva announces the presentation of a scientific abstract at the next International Conference on Fatty Liver
Daix (France), Long Island City (New York, United States), April 7, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small...
How Much Upside is Left in Inventiva S.A. Sponsored ADR (IVA)?
The average of price targets set by Wall Street analysts indicates a potential upside of 166.4% in Inventiva S.A. Sponsored ADR (IVA).
Inventiva announces filing of its 2021 Universal Registration Document and 2021 Annual Report on Form 20-F
Daix (France), Long Island City (New York, United States), March 11, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral smal...
Inventiva announces that its IND application for the Phase II combination trial with lanifibranor and empagliflozin i...
FDA assessment concludes that the Phase II combination trial, LEGEND, may proceed
Inventiva announces participation at several conferences in March 2022
Daix (France), Long Island City (New York, United States), March 1, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small...
Inventiva announces the schedule of publication and presentation of its 2021 Full-Year Financial Results
Daix (France), Long Island City (New York, United States), February 28, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral s...
Wall Street Analysts Think Inventiva S.A. Sponsored ADR (IVA) Could Surge 153%: Read This Before Placing a Bet
The consensus price target hints at a 152.7% upside potential for Inventiva S.A. Sponsored ADR (IVA).
Inventiva reports cash position and revenues for Full-Year 2021
Daix (France), Long Island City (New York, United States), February 14, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral s...
Inventiva receives a €4 million milestone payment from AbbVie for cedirogant Phase IIb initiation
Daix (France), Long Island City (New York, United States), January 31, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral sm...
Inventiva announces participation at several conferences in January and February 2022
Daix (France), Long Island City (New York, United States) , January 20, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral s...
Half-Year Review of Inventiva's Liquidity Contract with Kepler Cheuvreux
Daix (France), Long Island City (New York), January 14, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule th...
Inventiva to present at the 40th Annual J.P. Morgan Healthcare Conference
Daix (France), Long Island City (New York), December 16, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule t...
Inventiva Posts Results of Clinical Thorough QT Study Of Lanifibranor
Inventiva (NASDAQ: IVA) announced the results of a clinical thorough QT/QTc study demonstrating the safety of lanifibranor on cardiac electrical activity. The assessment of lanifibranor on cardiac repol...
Inventiva announces positive results of clinical thorough QT study conducted with lanifibranor
Daix (France), Long Island City (New York, United States) , December 6, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral s...
Inventiva reports 2021 Third Quarter Financial Information
Daix (France), Long Island City (New York, United States), November 10, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral s...
Fast Track Status Expanded For Inventiva's NASH Treatment
The FDA has decided that the Fast Track designation previously granted to Inventiva SA's (NASDAQ: IVA) lanifibranor in NASH encompasses the treatment of NASH patients with compensated cirrhosis. The dec...
Inventiva announces the implementation of an At-The-Market program in the United States
Daix (France), August 2, 2021 (GLOBE NEWSWIRE) – Inventiva S.A. (NASDAQ: IVA – EURONEXT PARIS: IVA) (the “Company”), a clinical-stage biotechnological company focused on the development of oral small mo...